PT656061E - Novas glicoformas do receptor do complemento 1 soluvel - Google Patents

Novas glicoformas do receptor do complemento 1 soluvel

Info

Publication number: PT656061E
Authority: PT; Portugal
Prior art keywords: scr1; complement; soluvel; glyphorules; receptor
Prior art date: 1992-08-07

Application number

PT93918681T

Other languages

English (en)

Inventor

Henry C Marsh Jr

Richard A G Smith

Chang-Jing Grace Yeh

John Lifter

Anne Mary Freeman

Michael L Gosselin

Original Assignee

Avant Immunotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-07

Filing date

1993-08-06

Publication date

2004-03-31

1993-08-06 Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc

2004-03-31 Publication of PT656061E publication Critical patent/PT656061E/pt

Links

102000016917 Complement C1 Human genes 0.000 title 1
108010028774 Complement C1 Proteins 0.000 title 1
238000000034 method Methods 0.000 abstract 2
238000002360 preparation method Methods 0.000 abstract 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 1
230000024203 complement activation Effects 0.000 abstract 1
102000006834 complement receptors Human genes 0.000 abstract 1
108010047295 complement receptors Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000035939 shock Effects 0.000 abstract 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
230000001732 thrombotic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Steroid Compounds (AREA)

PT93918681T 1992-08-07 1993-08-06 Novas glicoformas do receptor do complemento 1 soluvel PT656061E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/927,099 US5456909A (en)	1992-08-07	1992-08-07	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

Publications (1)

Publication Number	Publication Date
PT656061E true PT656061E (pt)	2004-03-31

Family

ID=25454172

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT93918681T PT656061E (pt)	1992-08-07	1993-08-06	Novas glicoformas do receptor do complemento 1 soluvel

Country Status (15)

Country	Link
US (3)	US5456909A (pt)
EP (1)	EP0656061B1 (pt)
JP (1)	JP3662250B2 (pt)
CN (1)	CN1089951A (pt)
AT (1)	ATE253591T1 (pt)
CA (1)	CA2141842C (pt)
DE (1)	DE69333287T2 (pt)
DK (1)	DK0656061T3 (pt)
ES (1)	ES2210241T3 (pt)
IL (1)	IL106558A (pt)
MX (1)	MX9304800A (pt)
PT (1)	PT656061E (pt)
TW (1)	TW386878B (pt)
WO (1)	WO1994003603A1 (pt)
ZA (1)	ZA935728B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395888B1 (en) *	1996-02-01	2002-05-28	Gilead Sciences, Inc.	High affinity nucleic acid ligands of complement system proteins
US5456909A (en) *	1992-08-07	1995-10-10	T Cell Sciences, Inc.	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
DK0730608T3 (da) *	1993-05-17	2002-07-22	Avant Immunotherapeutics Inc	Præparater omfattende komplementrelaterede proteiner og carbohydrater og fremgangsmåder til fremstilling og anvendelse af præparaterne
AU3729295A (en)	1994-09-23	1996-04-09	Alexion Pharmaceuticals, Inc.	Methods for the treatment of inflammatory joint disease
GB9614871D0 (en)	1996-07-15	1996-09-04	Smithkline Beecham Plc	Compounds
US6956107B2 (en) *	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation
EP3056516A1 (en) *	1998-02-20	2016-08-17	Genentech, Inc.	Inhibitors of complement activation
US7112327B2 (en) *	1998-02-20	2006-09-26	Tanox, Inc.	Inhibition of complement activation
SE0004808D0 (sv) *	2000-12-20	2000-12-20	Apbiotech Ab	Method for the purification of an enzyme
EP1438387A4 (en) *	2001-09-14	2004-10-13	Momenta Pharmaceuticals Inc	METHODS OF MAKING GLYCOMOLECULES WITH IMPROVED ACTIVITY, AND USES THEREOF
US20040214228A9 (en) *	2001-09-14	2004-10-28	Ganesh Venkataraman	Methods of evaluating glycomolecules for enhanced activities
US7530968B2 (en)	2003-04-23	2009-05-12	Valeritas, Inc.	Hydraulically actuated pump for long duration medicament administration
US7803931B2 (en)	2004-02-12	2010-09-28	Archemix Corp.	Aptamer therapeutics useful in the treatment of complement-related disorders
JP4507682B2 (ja) *	2004-04-26	2010-07-21	三菱化学株式会社	糖鎖分離方法、検体分析方法、液体クロマトグラフィー装置、並びに糖鎖分析方法及び糖鎖分析装置
EP2338511A3 (en)	2004-05-14	2012-07-25	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity
US9089636B2 (en)	2004-07-02	2015-07-28	Valeritas, Inc.	Methods and devices for delivering GLP-1 and uses thereof
US20070004625A1 (en) *	2005-06-30	2007-01-04	Li Liang-Man	Use of complement inhibitory proteins to treat spinal cord injury
EP1738763A1 (en)	2005-06-30	2007-01-03	AVANT Immunotherapeutics, Inc.	Use of complement inhibitory proteins to treat spinal cord injury
GB0518443D0 (en) *	2005-09-09	2005-10-19	Evolutec Ltd	Method of treating myasthenia gravis
DK2500030T4 (en) *	2005-11-04	2018-10-29	Genentech Inc	Use of complement pathway inhibitors for the treatment of eye diseases
AR058568A1 (es)	2005-12-20	2008-02-13	Bristol Myers Squibb Co	Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PT2253644E (pt)	2005-12-20	2014-01-23	Bristol Myers Squibb Co	Composições e métodos para a produção de uma composição
BRPI0708424A2 (pt)	2006-03-02	2011-05-31	Alexion Pharma Inc	prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
DK1991275T3 (en)	2006-03-08	2014-12-08	Archemix Llc	Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
HUE066795T2 (hu)	2006-03-15	2024-09-28	Alexion Pharma Inc	Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
WO2008030505A2 (en)	2006-09-05	2008-03-13	Alexion Pharmaceuticals, Inc.	Methods and compositions for the treatment of antibody mediated neuropathies
CA2666843C (en) *	2006-10-20	2015-06-16	Celldex Therapeutics, Inc.	Treatment of age-related macular degeneration and other diseases of the eye
CN106084055A (zh)	2006-11-02	2016-11-09	健泰科生物技术公司	人源化的抗‑d因子抗体
EP2586788B1 (en)	2007-07-09	2017-11-29	Genentech, Inc.	Prevention of disulfide bond reduction during recombinant production of polypeptides
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
TWI507525B (zh) *	2009-06-26	2015-11-11	Regeneron Pharma	具天然免疫球蛋白形式之易分離的雙專一性抗體
AU2011237442A1 (en)	2010-04-07	2012-10-18	Momenta Pharmaceuticals, Inc.	High mannose glycans
JP6092776B2 (ja) *	2010-09-15	2017-03-08	セルデックスセラピューティクスインコーポレイテッド	可溶性補体受容体Ｉ型（ｓＣＲ１）を用いる慢性腎症の処置
AU2011319746B2 (en)	2010-10-27	2015-07-30	Celldex Therapeutics, Inc.	Method of improving transplant function using soluble complement receptor type I (sCR1)
WO2012125553A2 (en)	2011-03-12	2012-09-20	Momenta Pharmaceuticals, Inc.	N-acetylhexosamine-containing n-glycans in glycoprotein products
CN103827134A (zh) *	2011-07-20	2014-05-28	泽普泰恩股份有限公司	多肽分离方法
US9695244B2 (en)	2012-06-01	2017-07-04	Momenta Pharmaceuticals, Inc.	Methods related to denosumab
WO2014018747A2 (en)	2012-07-26	2014-01-30	Momenta Pharmaceuticals, Inc.	Glycoproteins with anti-inflammatory properties
US10450361B2 (en)	2013-03-15	2019-10-22	Momenta Pharmaceuticals, Inc.	Methods related to CTLA4-Fc fusion proteins
ES2708759T3 (es)	2013-05-13	2019-04-11	Momenta Pharmaceuticals Inc	Procedimientos para el tratamiento de la neurodegeneración
MX2016001854A (es)	2013-08-12	2016-09-06	Genentech Inc	Composiciones y metodo para tratar condiciones asociadas con el complemento.
EP3058084A4 (en)	2013-10-16	2017-07-05	Momenta Pharmaceuticals, Inc.	Sialylated glycoproteins
SG11201608868PA (en)	2014-05-01	2016-11-29	Genentech Inc	Anti-factor d antibody variants and uses thereof
TW201730211A (zh)	2015-10-30	2017-09-01	建南德克公司	抗因子d抗體及結合物
JP2018536650A (ja)	2015-10-30	2018-12-13	ジェネンテック，インコーポレイテッド	抗ｄ因子抗体変異体コンジュゲート及びその使用
CN112118859A (zh) *	2018-05-16	2020-12-22	杰特有限公司	1型可溶性补体受体变体及其用途
EP3581203A1 (en) *	2018-06-11	2019-12-18	Laboratoire Français du Fractionnement et des Biotechnologies	Antibodies with increased activity in the digestive tract
TW202128264A (zh)	2019-09-25	2021-08-01	瑞士商赫孚孟拉羅股份公司	使用經預測之溶離緩衝鹽濃度的陽離子層析法
KR20250026267A (ko) *	2022-06-17	2025-02-25	씨에스엘 이노베이션 피티와이 엘티디	가용성 보체 수용체 및 이의 변이체의 정제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5212071A (en) *	1988-04-01	1993-05-18	The Johns Hopkins University	Nucleic acids encoding a human C3b/C4b receptor (CR1)
US5079353A (en) *	1987-12-02	1992-01-07	Chembiomed, Ltd.	Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
IL89790A (en) *	1988-04-01	2002-05-23	Johns Hopking University	Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US5256642A (en) *	1988-04-01	1993-10-26	The Johns Hopkins University	Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
CA2097825A1 (en) *	1990-12-06	1992-06-07	Henry C. Marsh, Jr.	Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) *	1992-08-07	1995-10-10	T Cell Sciences, Inc.	Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo

1992
- 1992-08-07 US US08/927,099 patent/US5456909A/en not_active Expired - Lifetime
1993
- 1993-08-02 IL IL10655893A patent/IL106558A/en not_active IP Right Cessation
- 1993-08-06 DE DE69333287T patent/DE69333287T2/de not_active Expired - Lifetime
- 1993-08-06 EP EP93918681A patent/EP0656061B1/en not_active Expired - Lifetime
- 1993-08-06 ES ES93918681T patent/ES2210241T3/es not_active Expired - Lifetime
- 1993-08-06 PT PT93918681T patent/PT656061E/pt unknown
- 1993-08-06 WO PCT/US1993/007406 patent/WO1994003603A1/en not_active Ceased
- 1993-08-06 AT AT93918681T patent/ATE253591T1/de not_active IP Right Cessation
- 1993-08-06 MX MX9304800A patent/MX9304800A/es unknown
- 1993-08-06 ZA ZA935728A patent/ZA935728B/xx unknown
- 1993-08-06 JP JP50558194A patent/JP3662250B2/ja not_active Expired - Lifetime
- 1993-08-06 DK DK93918681T patent/DK0656061T3/da active
- 1993-08-06 CA CA002141842A patent/CA2141842C/en not_active Expired - Lifetime
- 1993-08-07 CN CN93117624A patent/CN1089951A/zh active Pending
1994
- 1994-01-21 TW TW082108937A patent/TW386878B/zh not_active IP Right Cessation
1995
- 1995-06-06 US US08/470,867 patent/US5858969A/en not_active Expired - Lifetime
1998
- 1998-11-05 US US09/186,827 patent/US6057131A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL106558A (en)	1998-10-30
DK0656061T3 (da)	2004-03-15
ATE253591T1 (de)	2003-11-15
AU4804193A (en)	1994-03-03
US5456909A (en)	1995-10-10
MX9304800A (es)	1994-05-31
ES2210241T3 (es)	2004-07-01
TW386878B (en)	2000-04-11
CN1089951A (zh)	1994-07-27
ZA935728B (en)	1994-03-03
EP0656061B1 (en)	2003-11-05
IL106558A0 (en)	1993-12-08
WO1994003603A1 (en)	1994-02-17
US5858969A (en)	1999-01-12
CA2141842A1 (en)	1994-02-17
DE69333287T2 (de)	2004-09-23
EP0656061A1 (en)	1995-06-07
JPH08501773A (ja)	1996-02-27
CA2141842C (en)	2008-07-29
US6057131A (en)	2000-05-02
DE69333287D1 (de)	2003-12-11
AU670453B2 (en)	1996-07-18
JP3662250B2 (ja)	2005-06-22

Publication	Publication Date	Title
DK0656061T3 (da)	2004-03-15	Hidtil ukendte glycoformer af genopløselig komplementreceptor type 1
AR240251A1 (es)	1990-03-30	Metodo para preparar una composicion para tratamiento de infecciones virales y un metodo para sintetizar 3' azido 2', 3' dideoxiuridina destinada a la preparacion de dicha composicion.
GR3007096T3 (pt)	1993-07-30
EP0506840A4 (en)	1992-11-19	Method of treating ocular diseases by periocular administration of cyclosporine a or g
EP0154344A3 (en)	1990-06-13	Antiviral pharmaceutical preparations and methods for their use
MX9702932A (es)	1998-04-30	L-ribofuranosilnucleosidos.
DE69433013D1 (de)	2003-09-11	Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
KR100206481B1 (en)	1999-07-01	Galenic form for ocular administration and process for the preparation of same
HUT59000A (en)	1992-04-28	Process for producing pharmaceutical preparations containing 4-phenyl-1,2,3,4-tetrahydro-1-naphtalinamine-derivatives
CA2149329A1 (en)	1994-05-26	Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
MY109143A (en)	1996-12-31	Sulfonamido-and sulfonamidocarbonylpyridine 2-carboxamides and their pyridine-n-oxides, process for their preparation and their use as pharmaceuticals
ES8607732A1 (es)	1986-06-01	Procedimiento para producir un preparado implantable de un peptido regulador, uno de sus analogos o una de sus sales fisiologicamente compatibles.
GB2151244B (en)	1987-01-07	Insolubilized biocompatible hyaluronic acid preparations
MY109990A (en)	1997-10-31	Microfluidised particles of atovaquone and pharmaceutical preparation thereof
AU7807791A (en)	1991-12-05	Method of treating impotence
HUT63063A (en)	1993-07-28	Process for producing antibodies against cd44 cell surface glycoprotein and immunosuppressant pharmaceutical compositions comprising same
BG46599A3 (en)	1990-01-15	Method for preparing of benzene azetonitriles
GR3006815T3 (pt)	1993-06-30
CA2198706A1 (en)	1996-03-28	Methods for the treatment of inflammatory joint disease
ITMI922331A0 (it)	1992-10-09	Uso di paratormone suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto protermine ed in generale per il trattamento della gestazione
IT9067434A0 (it)	1990-06-14	Procedimento per migliorare l'efficacia terapeutica di corticosteroidi liposolubili e composizione per l'attuazione di tale procedimento
HU9202075D0 (en)	1992-10-28	Bcrf1 proteins of gamma-interferon inhibiting effect
MX9702926A (es)	1998-04-30	L-eritrosilnucleosidos.
AU2456888A (en)	1989-10-05	Monoclonal antibodies specific for HIV and hybridomas for their production
EP0282343A3 (en)	1989-11-02	Method to stimulate the immune response to specific antigens